Navigation Links
Expanding drug development horizons: Receptor behaviors observed in living cell membranes
Date:2/16/2011

Kyoto, Japan -- Unprecedented single molecule imaging movies of living cell membranes, taken by a research team based at Kyoto University and the University of New Mexico, have clarified a decades-old enigma surrounding receptor molecule behaviors. The results, appearing in the latest issue of the Journal of Cell Biology, promise to open the door to new possibilities for drug development.

The work focuses on G protein-coupled receptors (GPCRs), a class of molecules in cell membranes that comprise the largest superfamily in the human genome. In spite of being the focus of roughly half of modern drug development due to their key role in signaling across the membrane, until now it has not been well understood how GPCRs relay signals from the outside world into cells' interiors.

For over 15 years, debate regarding GPCRs' signaling mechanisms has centered on whether these molecules work alone (as monomers) or in pairs (dimers). Using formyl-peptide receptors (FPRs) as a model GPCR, the research team found that the two views are both partially correct.

"By developing a super-quantitation single-molecule imaging method, in which GPCR molecules are inspected one by one in living cell membranes," explained Rinshi Kasai of Kyoto University's Institute for Integrated Cell-Material Sciences (iCeMS) and lead author of the paper, "we are now able to actually 'see' that each individual FPR molecule moves around in the cell membrane, endlessly interconverting between monomers and dimers with different partners, completing each cycle within a quarter of a second."

According to iCeMS Professor Akihiro Kusumi, "We obtained a parameter called the dissociation constant, which will allow us to predict numbers of monomers and dimers if the total number of GPCRs in a cell is known. The ability of scientists to obtain such key numbers will be essential for understanding GPCR signaling, as well as defects leading to diseases from the neuronal to the immune systems. The implications for drug design, blocking signal amplification by monomer-dimer interconversion, are profoundly important."

The research team, funded in part by the Japan Science and Technology Agency (JST) and the Japanese education ministry MEXT, anticipates that their findings will have a broad impact on the further study of signal transduction in the cell membrane and conceptual and methodological development for drug discovery.


'/>"/>

Contact: Yutaka Iijima
yutaka-iijima@icems.kyoto-u.ac.jp
Institute for Integrated Cell-Material Sciences, Kyoto University
Source:Eurekalert

Related biology technology :

1. Expanding drug development horizons: Receptor behaviors observed in living cell membranes
2. Safe and Secure TV Channel Expanding Programming and Revenue Agreements for 2011 with Pentagons Military News Channel and other Security Industry Leaders
3. Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market
4. San Diego Region Awarded $4 Million Workforce Development Grant to Support Expanding Biofuels Industry
5. No Economic Slowdown for Expanding U.S. Medical Manufacturer
6. SynCo Bio Partners Increases its Capacities by Expanding its Quality Team
7. Expanding Indianas Breakthroughs in Health Information Technology (Exibhit Indiana): Initiative to Advance the States Health IT National Leadership and Assets Launched to Bring More Awareness to Sector
8. Biomedical Sciences Companies Expanding in Asia Invested More Than US$500 Million in Singapore
9. Robust Annual Growth Through 2012 in the Age-Related Macular Degeneration Market Will Be Driven by Expanding Use of Lucentis in Europe
10. Rapidly Expanding Ohio Bioscience Industry Drives New Workforce Training Program
11. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... NC (PRWEB) , ... June 23, 2016 , ... In ... University Hospital in Denmark detail how a patient who developed lymphedema after being treated ... tissue. The results could change the paradigm for dealing with this debilitating, frequent side ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
Breaking Biology Technology:
(Date:6/27/2016)... 2016 Research and Markets has announced the ... report to their offering. The ... to grow at a CAGR of 12.28% during the period ... an in-depth market analysis with inputs from industry experts. The report ... years. The report also includes a discussion of the key vendors ...
(Date:6/22/2016)... BETHESDA, Md. , June 22, 2016  The American ... by Trade Show Executive Magazine as one of ... Summit on May 25-27 at the Bellagio in ... based on the highest percentage of growth in each of ... number of exhibiting companies and number of attendees. The 2015 ...
(Date:6/22/2016)... LOS ANGELES , June 22, 2016 ... of identity management and verification solutions, has ... cutting edge software solutions for Visitor Management, ... ® provides products that add functional ... The partnership provides corporations and venues with ...
Breaking Biology News(10 mins):